Ingevec Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Ingevec hat ein Gesamteigenkapital von CLP84.8B und eine Gesamtverschuldung von CLP86.2B, wodurch sich der Verschuldungsgrad auf 101.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CLP242.3B bzw. CLP157.5B. Ingevec Das EBIT des Unternehmens beträgt CLP12.1B, so dass der Zinsdeckungsgrad 3.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CLP16.1B.

Wichtige Informationen

101.7%

Verhältnis von Schulden zu Eigenkapital

CL$86.23b

Verschuldung

Zinsdeckungsgrad	3.4x
Bargeld	CL$16.11b
Eigenkapital	CL$84.80b
Gesamtverbindlichkeiten	CL$157.55b
Gesamtvermögen	CL$242.35b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Jun 14

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Jan 11

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Apr 12

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Jan 11

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Ingevec S.A.'s (SNSE:INGEVEC) Performance Completely

Jan 26

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Jun 14

A Look At The Intrinsic Value Of Ingevec S.A. (SNSE:INGEVEC)

Feb 16

Slowing Rates Of Return At Ingevec (SNSE:INGEVEC) Leave Little Room For Excitement

Sep 02

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Jan 11

Key Things To Consider Before Buying Ingevec S.A. (SNSE:INGEVEC) For Its Dividend

Jan 26

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Jan 11

Did You Participate In Any Of Ingevec's (SNSE:INGEVEC) Incredible 423% Return?

Dec 23

We Wouldn't Rely On Ingevec's (SNSE:INGEVEC) Statutory Earnings As A Guide

Dec 01

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: INGEVECDie kurzfristigen Aktiva des Unternehmens (CLP118.1B) decken seine kurzfristigen Passiva (CLP128.5B) nicht.

Langfristige Verbindlichkeiten: INGEVECDie kurzfristigen Vermögenswerte des Unternehmens (CLP118.1B) übersteigen seine langfristigen Verbindlichkeiten (CLP29.0B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: INGEVECDie Nettoverschuldung im Verhältnis zum Eigenkapital (82.7%) wird als hoch angesehen.

Schulden abbauen: INGEVEC Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 117.6% auf 101.7% zurückgegangen.

Schuldendeckung: INGEVECDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (20.6%).

Zinsdeckung: INGEVECDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (3.4x Coverage) gut gedeckt.

Ingevec Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Recent updates

Third quarter 2024 earnings released: EPS: CL$2.82 (vs CL$2.07 in 3Q 2023)

Upcoming dividend of CL$2.90 per share

First quarter 2024 earnings released: EPS: CL$3.00 (vs CL$2.70 in 1Q 2023)

New major risk - Financial position

Full year 2023 earnings released: EPS: CL$9.70 (vs CL$9.30 in FY 2022)

Even With A 26% Surge, Cautious Investors Are Not Rewarding Ingevec S.A.'s (SNSE:INGEVEC) Performance Completely

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CL$2.07 (vs CL$2.24 in 3Q 2022)

New major risk - Financial position

Second quarter 2023 earnings released: EPS: CL$2.68 (vs CL$2.49 in 2Q 2022)

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Extensively

Full year 2022 earnings released: EPS: CL$9.30 (vs CL$8.60 in FY 2021)

A Look At The Intrinsic Value Of Ingevec S.A. (SNSE:INGEVEC)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Investor sentiment improved over the past week

Slowing Rates Of Return At Ingevec (SNSE:INGEVEC) Leave Little Room For Excitement

Second quarter 2022 earnings released: EPS: CL$2.49 (vs CL$2.08 in 2Q 2021)

First quarter 2022 earnings released: EPS: CL$2.70 (vs CL$2.20 in 1Q 2021)

Upcoming dividend of CL$4.30 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

These 4 Measures Indicate That Ingevec (SNSE:INGEVEC) Is Using Debt Reasonably Well

The Returns At Ingevec (SNSE:INGEVEC) Aren't Growing

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CL$2.21 (vs CL$0.97 in 3Q 2020)

Second quarter 2021 earnings released: EPS CL$2.08 (vs CL$0.06 in 2Q 2020)

Here's What's Concerning About Ingevec's (SNSE:INGEVEC) Returns On Capital

First quarter 2021 earnings released: EPS CL$2.20 (vs CL$1.72 in 1Q 2020)

Upcoming dividend of CL$1.56 per share

Calculating The Fair Value Of Ingevec S.A. (SNSE:INGEVEC)

Upcoming dividend of CL$1.56 per share

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS CL$5.20 (vs CL$7.80 in FY 2019)

New 90-day high: CL$90.00

Here’s What’s Happening With Returns At Ingevec (SNSE:INGEVEC)

Is Ingevec S.A.'s (SNSE:INGEVEC) ROE Of 9.7% Impressive?

Key Things To Consider Before Buying Ingevec S.A. (SNSE:INGEVEC) For Its Dividend

Does Ingevec (SNSE:INGEVEC) Have A Healthy Balance Sheet?

Did You Participate In Any Of Ingevec's (SNSE:INGEVEC) Incredible 423% Return?

New 90-day low: CL$79.78

We Wouldn't Rely On Ingevec's (SNSE:INGEVEC) Statutory Earnings As A Guide

Third quarter 2020 earnings released: EPS CL$0.97

New 90-day low: CL$82.25

New 90-day low: CL$85.20

First half earnings released

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen